CMDBS are synthetic polysaccharides that inhibit thrombin through a novel mechanism involving direct interaction and HCII catalysis, showing potential as novel anticoagulants.
No takes yet. Share an insight, caveat, or question.
CMDBS merits further preclinical development as an anticoagulant; leaves open translation to human use pending clinical trials.
Raucourt et al. (1998) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: